Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
Matthijs P. Raadsen, Christine Dahlke, Anahita Fathi, Mart M. Lamers, Petra van den Doel, Luca M. Zaeck, Martin E. van Royen, Erwin de Bruin, Reina S. Sikkema, Marion Koopmans, Eric C. M. Van Gorp, Gerd Sutter, Rory D. de Vries, Marylyn M. Addo, Bart L. Haagmans
Abstract
Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)-associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.
Topics & Concepts
MonkeypoxVirologyVacciniaVirusMiddle East respiratory syndrome coronavirusNeutralizing antibodyOrthopoxvirusAntibodyCoronavirusVaccinationPoxviridaeBiologyMedicineImmunologyCoronavirus disease 2019 (COVID-19)Infectious disease (medical specialty)Recombinant DNAGenePathologyDiseaseBiochemistryPoxvirus research and outbreaksBacillus and Francisella bacterial researchViral gastroenteritis research and epidemiology